Formulations for the oral administration of therapeutic agents and related methods
The present application relates to an oral formulation of amphotericin B and other therapeutic agents, which formulation comprises one or more fatty acid glycerol esters and one or more PEG modified phospholipids or fatty acid esters. The formulation provides enhanced bioavailability and/or increased stability of the therapeutic agent at the low pH found in gastric fluid.
1. An amphotericin B formulation, comprising,
(a) amphotericin B;
(b) one or more fatty acid glycerol esters; and
(c) one or more polyethylene oxide-containing fatty acid esters.
2. The formulation of claim 1 , wherein amphotericin B is present in the formulation in an amount from about 0.5 to about 10 mg/mL of the formulation.
3. The formulation of claim 1 , wherein the fatty acid glycerol esters comprise from about 32 to about 52% by weight fatty acid monoglycerides.
4. The formulation of claim 1 , wherein the fatty acid glycerol esters comprise from about 30 to about 50% by weight fatty acid diglycerides.
5. The formulation of claim 1 , wherein the fatty acid glycerol esters comprise from about 5 to about 20% by weight fatty acid triglycerides.
6. The formulation of claim 1 , wherein the polyethylene oxide-containing fatty acid esters comprise a polyethylene oxide ester of a C8-C22 saturated fatty acid.
7. The formulation of claim 1 , wherein the polyethylene oxide-containing fatty acid esters comprise a polyethylene oxide ester of a C12-C18 saturated fatty acid.
8. The formulation of claim 1 , wherein the polyethylene oxide-containing fatty acid esters is selected from the group consisting of lauric acid esters, palmitic acid esters, stearic acid esters, and mixtures thereof.
9. The formulation of claim 1 , wherein the polyethylene oxide-containing fatty acid esters comprise a polyethylene oxide having an average molecular weight of from about 750 to about 2000.
10. The formulation of claim 1 , wherein the ratio of the fatty acid glycerol esters to polyethylene oxide-containing fatty acid esters is from about 20:80 to about 80:20 v/v.
11. The formulation of claim 1 , wherein the ratio of the fatty acid glycerol esters to polyethylene oxide-containing fatty acid esters is about 60:40 v/v.
12. The formulation of claim 1 , wherein the formulation is a self-emulsifying drug delivery system.
13. A method for treating an infectious disease treatable by the administration of amphotericin B, comprising administering to a subject in need thereof a therapeutically effective amount of an amphotericin B formulation of claim 1 .
14. The method of claim 13 , wherein the formulation is administered orally or topically.
15. The method of claim 14 , wherein the infectious disease is a fungal infection, visceral leishmaniasis, cutaneous leishmaniasis, Chagas disease, or Febrile neutropenia.
16. The method of claim 15 , wherein the fungal infection is aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, crytococcosis, histoplasmosis, mucormycosis, paracoccidioidomycosis, or sporotrichosis.
17. The formulation of claim 1 , wherein the ratio of the fatty acid glycerol esters to polyethylene oxide-containing fatty acid esters is about 50:50 v/v.